In one paragraphArticle in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors at 4 institutions in 1 country.
Richard T EastmanDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0003-3580-380X Xi-Ping HuangDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0002-2585-653X Patricia DranchakDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-1349-4885 Ty C VossDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0009-0002-8750-2478 Sandeep RanaDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0001-5802-5970 Jonathan H ShrimpDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0001-9872-942X Alex D WhiteDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2180-2136 Bryan L RothDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.ORCID 0000-0002-0561-6520 James IngleseDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-7332-5717 Jayme L DahlinNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0003-4151-9944 National Institutes of Health · USCornell University · USUniversity of North Carolina at Chapel Hill · USUniversity of California, San Francisco · US
Funding
SYNAPTIC MECHANISMS OF GENERAL ANESTHETIC ACTIONR01GM058055 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI HEMMINGS, HUGH C · 1998 to 2023
$10.1MEnergetics of Channel-Bilayer InteractionsR01GM021342 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI ANDERSEN, OLAF S. · 1985 to 2021
$9.9MDevelopment and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5MPhenotypic Assay Design and Development for Rare and Neglected DiseasesZIATR000052 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI INGLESE, JAMES · 2015 to 2025
$3.7MIntramural NIH HHS ZIA TR000052NIGMS NIH HHS R01 GM021342NIGMS NIH HHS R01 GM058055NIGMS NIH HHS R35 GM122481
6 · The paper itselfAbstract
Since it was proposed as a potential host-directed antiviral agent for SARS-CoV-2, the antiparasitic drug ivermectin has been investigated thoroughly in clinical trials, which have provided insufficient support for its clinical efficacy. To examine the potential for ivermectin to be repurposed as an antiviral agent, we therefore undertook a series of preclinical studies. Consistent with early reports, ivermectin decreased SARS-CoV-2 viral burden in
Indexed as
antiviralcytotoxicitydrug repurposingivermectinmembrane bilayerSARS-CoV-2
Identifiers
PMID37961094
PMCPMC10634736
OpenAlexW4387908535
What OpenQuestion holds
Textmetadata
LicenceCC0
Read underepoch 390